Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841870 | 0.92 | TSHR (0.33) | KCNH2 | |
| SCHEMBL841648 | 0.89 | TSHR (0.32) | — | |
| SCHEMBL841608 | 0.89 | TSHR (0.32) | — | |
| SCHEMBL841265 | 0.86 | TSHR (0.33) | — | |
| SCHEMBL10225595 | 0.85 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL842083 | 0.85 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL840929 | 0.83 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL15383389 | 0.83 | SIGMAR1 (0.38) | KCNH2 | |
| SCHEMBL23192225 | 0.82 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL15383397 | 0.81 | KCNH2 (0.38) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11505535-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3662911-A1 | COMBINATION OF AZACITIDINE AND PRACINOSTAT TO TREAT MYELODYSPLASTIC SYNDROME (MDS) | MEI Pharma, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-2914254-B1 | COMBINATION THERAPIES TO TREAT CHEMORESISTANT CANCERS | MEI PHARMA INC (US) | 2020-01-08 | — | — | EP | disclosed |
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2016-02-25 | — | — | US | disclosed |
| US-9266882-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9217015-B2 | Cyclosporin derivatives for the treatment and prevention of a viral infection | S&T GLOBAL INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150038703-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HELSINN HEALTHCARE SA (CH) | 2015-02-05 | — | — | US | disclosed |
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2013-11-14 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD. (SG) | 2010-04-29 | — | — | US | disclosed |
| US-7666880-B2 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2010-02-23 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | S*BIO PTE LTD. (SG) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505535-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | KCNH2 1428/4885HTR2A 752/4885 |
| US-20160052972-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | KCNH2 3263/4885HTR2A 4506/4885 |
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | KCNH2 3688/4885HTR2A 2592/4885 |
| US-20080085896-A1 | Hydroxamate compounds which are inhibitors of histone deacetylase; may be useful as medicaments for treatment of proliferative disorders as well as other diseases involving, relating to, or associated with enzymes having histone deacetylase activities such as neurodegenerative, cardiovascular disorders | HDAC1, HDAC5, HDAC11 | KCNH2 3929/4885HTR2A 1705/4885 |
| US-20100105721-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC1, HDAC2, HDAC5 | KCNH2 3292/4885HTR2A 1769/4885 |
| US-20130303438-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, ICOS | KCNH2 3263/4885HTR2A 4506/4885 |
| US-20150258068-A1 | COMBINATION THERAPIES | HDAC1, HDAC8, HDAC5 | KCNH2 4347/4885HTR2A 3106/4885 |
| US-20150038703-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC1, HDAC2, HDAC5 | KCNH2 3292/4885HTR2A 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.